Form 4: BioNTech Officer Reports Stock Option and PSU Grants

BioNTech SE reports on May 12, 2026, that Chief Legal Officer and Chief Business Officer Ryan James Timothy Patrick was granted stock options and performance share units.

Summary

• Ryan James Timothy Patrick, Chief Legal Officer and Chief Business Officer of BioNTech SE, reported transactions on May 12, 2026.
• These transactions involved the acquisition of stock options and performance share units (PSUs).
• The stock options grant a right to buy 12,586 ordinary shares with an exercise price of EUR 89.38, subject to adjustments.
• The PSUs represent the economic equivalent of 10,069 ordinary shares and can be settled in shares, ADSs, or cash.
• Both options and PSUs vest annually over four years, with exercisability commencing four years after the grant date, contingent on continued service and performance targets for PSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports on routine executive compensation grants rather than significant financial or strategic developments.

Positives

• Grant of stock options and performance share units indicates potential future equity value for a key executive.
• The structure of the PSUs, tied to performance targets, aligns executive incentives with company performance and shareholder value.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• Performance Share Units (PSUs) are subject to achievement of certain performance targets based on the market price of BioNTech's ordinary shares relative to the Nasdaq Biotechnology Index.
• Stock options are subject to adjustments to ensure the trading price of an American Depositary Share (ADS) does not exceed 800% of the grant date exercise price.
• Vesting and exercisability are contingent upon the reporting person's continued service through specified dates.

Future Outlook

The future outlook is tied to the vesting and performance conditions of the granted stock options and performance share units, which are exercisable from May 12, 2030, and expire on May 12, 2036. The performance of BioNTech's shares relative to the Nasdaq Biotechnology Index will impact the value of the PSUs.

Management Comments

• The filing is a statement of changes in beneficial ownership and does not contain direct management comments on financial performance or strategy.

Industry Context

StockSavvy.ai notes that the granting of stock options and performance share units to key executives is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize talent, aligning their interests with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The grants align executive interests with long-term shareholder value, potentially leading to better company performance. However, the dilutive effect of future share issuances upon option exercise or PSU settlement should be considered.
• Employees: The compensation structure for senior management can influence overall company culture and compensation philosophy.
• Management: The reporting person benefits from potential future equity gains, contingent on performance and continued employment.

Next Steps

• Vesting of stock options and performance share units over the next four years.
• Achievement of performance targets for PSUs.
• Potential exercise of stock options from May 12, 2030, onwards.

Key Dates

Keywords

BioNTech SE, BNTX, Form 4, Stock Options, Performance Share Units, Executive Compensation, Insider Trading, SEC Filing, Ryan James Timothy Patrick, Chief Legal Officer, Chief Business Officer